Efinopegdutide

N/A

Report date: 2026/05/11 20:01:57

Base Information

Drug NameEfinopegdutide
Drug Alias NameLAPS-GLP/GlucagonLAPS-GLP-1/GCGLAPS-GCG/GLP-1LAPS GLP/GCGOxyntomodulin immunoglobulin conjugate +[9] 
ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucagon receptor
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2Kidney Failure, Chronic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[36] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co LtdMerck Sharp & Dohme LLCMSD R&D（China）Co Ltd
Inactive CompaniesJanssen Pharmaceutical KkJanssen Research & Development Llc
Active IndicationsHepatic InsufficiencyMetabolic Dysfunction-Associated Steatotic Liver DiseaseLiver Diseases
Inactive IndicationsObesityDiabetes Mellitus, Type 2Kidney Failure, Chronic

Other Information

ATC CodeN/A
Related LinksN/A